48,479
edits
Difference between revisions of "Colorectal tumours"
Jump to navigation
Jump to search
→MSI classification: +prognosis
(→MSI classification: +prognosis) |
|||
| Line 158: | Line 158: | ||
*MSI-H >= 30% of loci have abnormality. | *MSI-H >= 30% of loci have abnormality. | ||
*MSI-L <30% of loci have abnormality. | *MSI-L <30% of loci have abnormality. | ||
Note: | |||
*In the context of '''''no''''' chemotherapy, individuals with MSI-H tumours have a superior outcome to those with MSI-L tumours.<ref name=pmid12867608>{{Cite journal | last1 = Ribic | first1 = CM. | last2 = Sargent | first2 = DJ. | last3 = Moore | first3 = MJ. | last4 = Thibodeau | first4 = SN. | last5 = French | first5 = AJ. | last6 = Goldberg | first6 = RM. | last7 = Hamilton | first7 = SR. | last8 = Laurent-Puig | first8 = P. | last9 = Gryfe | first9 = R. | title = Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. | journal = N Engl J Med | volume = 349 | issue = 3 | pages = 247-57 | month = Jul | year = 2003 | doi = 10.1056/NEJMoa022289 | PMID = 12867608 }}</ref> | |||
**With chemotherapy the outcomes are similar. | |||
===Gross=== | ===Gross=== | ||